Lilly changes primary endpoint of mild AD trial

Eli Lilly and Co. (NYSE:LLY) said Tuesday it is changing one of two co-primary endpoints to a secondary endpoint in the Phase III EXPEDITION3 trial of solanezumab ( LY2062430) to treat mild Alzheimer's disease (AD).

The trial's original co-primary endpoints were change from baseline in the 14-item AD Assessment Scale-Cognitive Subscore (ADAS-Cog14) and the Alzheimer's Disease Cooperative Study-Instrumental Activities of Daily Living (ADCS-iADL) score. Lilly now is making ADAS-Cog14 the single primary endpoint. ...